Knowledge Library

Throughout much of the development in ex vivo gene therapies, Lentiviral vectors have been a preferred vehicle due to their ability to integrate into the host cell genome and infect dividing as well as non-dividing cells. With the continued evolution of CAR-T therapies to include new modalities such as allogeneic and in vivo treatments, flexible …Read More >

For developers involved in AAV therapeutics, three key considerations are critical to successful commercialization: Quality, Quantity, and Speed.  In this webinar, Dr. Jason King demonstrate how OXGENE’s AAV plasmid system together with WuXi ATU’s AAV suspension manufacturing platform delivers higher titers and improved quality compared to industry standard in any serotype, at any scale and …Read More >

 In recent years, the demand for cell and gene therapy has increased substantially. With the success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality Plasmid DNA, key prominent market challenges are capacity availability, accelerated TAT and affordability. In this presentation, WuXi Advanced Therapies will …Read More >

 Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced Technologies recently announced the expansion of its service capabilities by offering a fully integrated CAR-T cell therapy platform to help accelerate the timeline for cell and gene therapy development, manufacturing, and release while providing greater predictability. This …Read More >

The field of gene therapy has experienced significant growth in recent years. Adeno-associated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that …Read More >